News & Events
New biomarkers to predict progression in MS
Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS
Natalizumab improves walking in relapsing-remitting MS
Natalizumab is associated with clinically meaningful improvements in walking speeds
Disease-modifying drugs may reduce disability progression in relapsing-remitting MS
Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared…
Online cognitive training in Germany
DMSG’s training programme aims to help people with MS improve cognition functions
Working with MS Home in China
Abdelfatah Ibrahim’s visit focused on supporting a new MS/NMO group
The role deep grey matter in the brain plays in MS
Deep grey matter is profoundly involved in the disease progression of MS patients
The role of iron and brain damage in MS
The presence of iron could help us understand the MS inflammation process
Progressive MS and disease-modifying drugs
Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset…
Improving diagnosis of MS
Over 35 per cent of patients with clinically isolated syndrome were diagnosed earlier when applying the 2010…
Disappointing results from fingolimod trial in primary progressive MS
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Positive outcomes in changing from interferon to glatiramer acetate
Switching patients with relapsing-remitting MS from interferon to glatiramer acetateis associated with positive treatment outcomes
No target met unless met for all
MS International Federation calls on the UN to ensure new global goals benefit all - including people…